Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
Safety of Hydroxychloroquine among Outpatient Clinical Trial Participants for COVID-19
Lofgren et al., Open Forum Infectious Diseases, doi:10.1093/ofid/ofaa500 (date from earlier preprint)
Lofgren et al., Safety of Hydroxychloroquine among Outpatient Clinical Trial Participants for COVID-19, Open Forum Infectious Diseases, doi:10.1093/ofid/ofaa500 (date from earlier preprint)
Sep 2020   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Analysis of 2,795 outpatients not showing significant safety concerns with HCQ. No deaths were related to HCQ. There was one serious event requiring hospitalization, identical to the frequency with placebo.
Lofgren et al., 21 Sep 2020, peer-reviewed, 26 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Abstract: Open Forum Infectious Diseases MAJOR ARTICLE Safety of Hydroxychloroquine Among Outpatient Clinical Trial Participants for COVID-19 Sarah M. Lofgren,1, Melanie R. Nicol,1 Ananta S. Bangdiwala,1 Katelyn A. Pastick,1, Elizabeth C. Okafor,1 Caleb P. Skipper,1 Matthew F. Pullen,1 Nicole W. Engen,1 Mahsa Abassi,1 Darlisha A. Williams,1 Alanna A. Nascene,1 Margaret L. Axelrod,2 Sylvain A. Lother,3 Lauren J. MacKenzie,3 Glen Drobot,3 Nicole Marten4, Matthew P. Cheng,6,7 Ryan Zarychanski,3,4 Ilan S. Schwartz,5 Michael Silverman,8 Zain Chagla,9 Lauren E. Kelly,4 Emily G. McDonald,6,7 Todd C. Lee,6,7 Kathy H Hullsiek,1 David R. Boulware,1 and Radha Rajasingham1, Background.   Use of hydroxychloroquine in hospitalized patients with coronavirus disease 2019 (COVID-19), especially in combination with azithromycin, has raised safety concerns. Here, we report safety data from 3 outpatient randomized clinical trials. Methods.   We conducted 3 randomized, double-blind, placebo-controlled trials investigating hydroxychloroquine as preexposure prophylaxis, postexposure prophylaxis, and early treatment for COVID-19 using an internet-based design. We excluded individuals with contraindications to hydroxychloroquine. We collected side effects and serious adverse events. We report descriptive analyses of our findings. Results.   We enrolled 2795 participants. The median age of research participants (interquartile range) was 40 (34–49) years, and 59% (1633/2767) reported no chronic medical conditions. Overall 2544 (91%) participants reported side effect data, and 748 (29%) reported at least 1 medication side effect. Side effects were reported in 40% with once-daily, 36% with twice-weekly, 31% with once-weekly hydroxychloroquine, compared with 19% with placebo. The most common side effects were upset stomach or nausea (25% with oncedaily, 19% with twice-weekly, and 18% with once-weekly hydroxychloroquine, vs 11% for placebo), followed by diarrhea, vomiting, or abdominal pain (23% for once-daily, 17% twice-weekly, and 13% once-weekly hydroxychloroquine, vs 7% for placebo). Two individuals were hospitalized for atrial arrhythmias, 1 on placebo and 1 on twice-weekly hydroxychloroquine. No sudden deaths occurred. Conclusions.   Data from 3 outpatient COVID-19 trials demonstrated that gastrointestinal side effects were common but mild with the use of hydroxychloroquine, while serious side effects were rare. No deaths occurred related to hydroxychloroquine. Randomized clinical trials, in cohorts of healthy outpatients, can safely investigate whether hydroxychloroquine is efficacious for COVID-19. ClinicalTrials.gov Identifier. NCT04308668 for postexposure prophylaxis and early treatment trials; NCT04328467 for preexposure prophylaxis trial. Keywords.: COVID-19; hydroxychloroquine; safety; SARS-Cov2; side effects. Hydroxychloroquine has in vitro antiviral activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [1, 2]. While in vitro data suggest that both chloroquine and hydroxychloroquine have activity against SARS-CoV-2 replication, the latter is generally considered less toxic and better tolerated. However, clinical data to date demonstrate no conclusive efficacy of hydroxychloroquine for the treatment or prevention of coronavirus disease 2019 (COVID-19) [3–5]. Both Received 17 July 2020; editorial decision 13 October 2020; accepted 15 October 2020. Correspondence: Sarah Lofgren, MD, 689 23rd Avenue S.E., Minneapolis, MN..
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit